Nakagawa-Saito, Y.; Mitobe, Y.; Suzuki, S.; Togashi, K.; Sugai, A.; Kitanaka, C.; Okada, M.
Domatinostat Targets the FOXM1–Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents. Int. J. Mol. Sci. 2023, 24, 10817.
https://doi.org/10.3390/ijms241310817
AMA Style
Nakagawa-Saito Y, Mitobe Y, Suzuki S, Togashi K, Sugai A, Kitanaka C, Okada M.
Domatinostat Targets the FOXM1–Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents. International Journal of Molecular Sciences. 2023; 24(13):10817.
https://doi.org/10.3390/ijms241310817
Chicago/Turabian Style
Nakagawa-Saito, Yurika, Yuta Mitobe, Shuhei Suzuki, Keita Togashi, Asuka Sugai, Chifumi Kitanaka, and Masashi Okada.
2023. "Domatinostat Targets the FOXM1–Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents" International Journal of Molecular Sciences 24, no. 13: 10817.
https://doi.org/10.3390/ijms241310817
APA Style
Nakagawa-Saito, Y., Mitobe, Y., Suzuki, S., Togashi, K., Sugai, A., Kitanaka, C., & Okada, M.
(2023). Domatinostat Targets the FOXM1–Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents. International Journal of Molecular Sciences, 24(13), 10817.
https://doi.org/10.3390/ijms241310817